Aventis
| Aventis
|
|
|---|---|
 |
|
| legal form | Société anonyme |
| founding | End of 1999 (merger of Hoechst AG with parts of the Rhône-Poulenc company ) |
| resolution | Mid 2004 |
| Reason for dissolution | Merger with Sanofi-Synthélabo to form Sanofi-Aventis |
| Seat | Strasbourg , France |
| Branch | Pharmacy , pesticides |
The company Aventis , based in Strasbourg was one of the largest and most short-lived pharmaceutical companies in the world (1999-2004).
history
The company was formed in 1999 from the merger of Hoechst ( Frankfurt am Main ) with the French pharmaceutical company Rhône-Poulenc ( Lyon ). The Höchst industrial park in Frankfurt-Höchst is one of the largest European production and research locations. The pharmaceutical division of the group, Aventis Pharma AG , was based in Frankfurt am Main, the crop protection division of the new group as Aventis Crop Science in Lyon.
In 2003 Aventis sold the group's crop protection division to its competitor Bayer . This resulted in the Bayer CropScience subgroup and Aventis has since briefly been a pure pharmaceutical company.
In mid-2004, the rest of Aventis merged with the French pharmaceutical company Sanofi-Synthélabo . The new company Sanofi-Aventis became the largest pharmaceutical company in Europe. Formally, the takeover was a merger of equals, in fact it was a takeover that was preceded by a so-called hostile takeover offer from Sanofi-Synthélabo in January 2004 .
Although Sanofi-Synthélabo was significantly smaller than Aventis, the company had a high valuation on the stock exchange due to its rapid growth and was in a relatively safe starting position, as it had two major shareholders, L'Oréal and Total , who supported the takeover strategy. The French government had also welcomed the merger in order to create a “European champion”. The German government was neutral so as not to jeopardize possible future takeovers of French companies by Germans.
Individual evidence
- ^ A b Michael Wortmann: Complex and global strategies and structures of multinational companies . Springer-Verlag, 2008, ISBN 978-3-531-16315-4 , pp. 118 ( limited preview in Google Book search).
- ↑ Uwe Michel, Ronald Gleich, Péter Horváth: Finance Controlling Strategic and operational management of liquidity . Haufe-Lexware, 2012, ISBN 978-3-648-02243-6 , p. 191 ( limited preview in Google Book search).
- ↑ Catharina Rudy: Conveying a new corporate ideology using the example of Aventis Pharma . diplom.de, 2002, ISBN 3-8324-5223-0 , p. 34 ( limited preview in Google Book search).
- ↑ Brigitte Ahrens: The takeover process of Aventis by Sanofi-Synthelabo . GRIN Verlag, 2005, ISBN 3-638-40136-7 , p. 4..10 ( limited preview in Google Book Search).
- ^ Lawton Robert Burns: The Business of Healthcare Innovation . Cambridge University Press, 2012, ISBN 1-107-02497-8 , pp. 140 ( limited preview in Google Book search).
- ↑ Nicole Munk: Insolvency prophylaxis for Germany Ways to reorganize the state and economy. Vision of a second German economic miracle . Springer-Verlag, 2013, ISBN 978-3-322-84558-0 , p. 529 ( limited preview in Google Book search).
- ^ Simon Grand, Daniel Bartl: Executive Management in Practice Development - Implementation - Application . Campus Verlag, 2011, ISBN 978-3-593-39548-7 , pp. 227 ( limited preview in Google Book search).